New immunotherapy drug could be first defense against advanced skin cancer
NCT ID NCT06981325
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing the drug cemiplimab as a first-line treatment for people with advanced basal cell carcinoma who have not received prior therapy. The study will enroll 34 participants and measure how many patients see their tumors shrink or disappear after six months. Cemiplimab works by helping the immune system recognize and attack cancer cells, offering a potential alternative to current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cemiplimab (a cancer immunotherapy drug that helps the immune system attack cancer cells)
What this could lead to
If it works, this could offer a new first-line treatment option for advanced basal cell carcinoma, potentially shrinking tumors and delaying progression without needing prior therapies.
What could go wrong
This is a small, early-phase trial with only 34 participants, so results may not apply to everyone. Immunotherapy can cause side effects like inflammation in healthy organs, and the drug may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Helios Klinikum Erfurt
RECRUITINGErfurt, Germany
-
Helios Klinikum Oberhausen
RECRUITINGOberhausen, Germany
-
Johannes Wesling Klinikum
RECRUITINGMinden, Germany
-
Nationales Centrum für Tumorerkrankungen (NCT)
RECRUITINGHeidelberg, Germany
-
Universitätsklinikum Erlangen
RECRUITINGErlangen, Germany
-
Universitätsklinikum Leipzig
RECRUITINGLeipzig, Germany
-
Universitätsklinikum Tübingen
RECRUITINGTübingen, Germany